$76.4M
1 filing since 2025 · latest Equity filed
Surrozen, Inc. is a biotechnology firm headquartered in South San Francisco, California, dedicated to pioneering innovative regenerative medicines through the activation of the Wnt signaling pathway. This critical mechanism serves as a foundation for tissue repair and regeneration, positioning Surrozen at the forefront of advanced therapeutic solutions for diverse medical conditions.
What sets it apart
Surrozen's unique focus on harnessing the Wnt signaling pathway distinguishes it from traditional approaches to regenerative medicine, providing targeted therapies for complex diseases with unmet medical needs.
SZN-1326 is a Fzd5-targeted antibody specifically designed to treat moderate to severe ulcerative colitis by stimulating Wnt signaling in the intestinal epithelium, thereby promoting tissue repair and healing.
